Emergent Biosolutions’ (EBS) Hold Rating Reiterated at Cowen

Cowen restated their hold rating on shares of Emergent Biosolutions (NYSE:EBS) in a research report sent to investors on Wednesday, AnalystRatings.com reports. They currently have a $60.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Co lowered their target price on Emergent Biosolutions to $61.00 and set a market perform rating for the company in a report on Friday, May 10th. Zacks Investment Research downgraded Emergent Biosolutions from a buy rating to a hold rating in a report on Monday, April 8th. Cantor Fitzgerald restated a buy rating and set a $75.00 price objective on shares of Emergent Biosolutions in a report on Thursday, May 2nd. Finally, ValuEngine downgraded Emergent Biosolutions from a buy rating to a hold rating in a report on Wednesday, July 17th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $70.33.

EBS stock traded up $0.63 during mid-day trading on Wednesday, reaching $44.82. The company’s stock had a trading volume of 714,880 shares, compared to its average volume of 243,146. The company has a market capitalization of $2.27 billion, a P/E ratio of 19.24, a price-to-earnings-growth ratio of 0.72 and a beta of 1.60. The business’s 50 day moving average price is $44.93. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.28 and a current ratio of 2.13. Emergent Biosolutions has a 12 month low of $39.64 and a 12 month high of $73.89.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). The business had revenue of $243.20 million during the quarter, compared to the consensus estimate of $217.94 million. Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.07 earnings per share. Research analysts anticipate that Emergent Biosolutions will post 3.06 earnings per share for the current fiscal year.

In other news, Director Kathryn C. Zoon sold 1,376 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total transaction of $59,704.64. Following the completion of the sale, the director now owns 24,379 shares in the company, valued at $1,057,804.81. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 14.10% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Emergent Biosolutions by 2.7% during the first quarter. BlackRock Inc. now owns 6,736,576 shares of the biopharmaceutical company’s stock valued at $340,330,000 after acquiring an additional 176,339 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of Emergent Biosolutions by 47.3% during the first quarter. Neuberger Berman Group LLC now owns 1,922,108 shares of the biopharmaceutical company’s stock valued at $97,105,000 after buying an additional 617,486 shares during the last quarter. Norges Bank purchased a new position in shares of Emergent Biosolutions during the fourth quarter valued at approximately $49,581,000. Fisher Asset Management LLC boosted its position in shares of Emergent Biosolutions by 23.3% during the second quarter. Fisher Asset Management LLC now owns 657,957 shares of the biopharmaceutical company’s stock valued at $31,786,000 after buying an additional 124,413 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in shares of Emergent Biosolutions during the first quarter valued at approximately $26,644,000. Hedge funds and other institutional investors own 86.12% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.